

This article was downloaded by:

On: 25 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Novel Enamine Derivatives of 5,6-Dihydro-2'-Deoxyuridine Formed in Reductive Amination of 5-Formyl-2'-Deoxyuridine

Elzbieta Sochacka^a; Damian Smuga^a

^a Institute of Organic Chemistry, Technical University of Lodz, Lodz, Poland

To cite this Article Sochacka, Elzbieta and Smuga, Damian(2008) 'Novel Enamine Derivatives of 5,6-Dihydro-2'-Deoxyuridine Formed in Reductive Amination of 5-Formyl-2'-Deoxyuridine', *Nucleosides, Nucleotides and Nucleic Acids*, 27: 9, 1045 – 1060

To link to this Article: DOI: 10.1080/15257770802271789

URL: <http://dx.doi.org/10.1080/15257770802271789>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NOVEL ENAMINE DERIVATIVES OF 5,6-DIHYDRO-2'-DEOXYURIDINE FORMED IN REDUCTIVE AMINATION OF 5-FORMYL-2'-DEOXYURIDINE

Elzbieta Sochacka and Damian Smuga

Institute of Organic Chemistry, Technical University of Lodz, Lodz, Poland

□ *Reductive amination of 5-formyl-3',5'-di-O-acetyl-2'-deoxyuridine with primary amines and sodium triacetoxyborohydride ($\text{NaBH}(\text{OAc})_3$) afforded novel enamine derivatives of 5,6-dihydro-2'-deoxyuridine as a result of unexpected 1,4-conjugate reduction of intermediate Schiff bases in addition to the secondary amine derivatives of 2'-deoxyuridine, typical 1,2-reduction products.*

Keywords Modified nucleosides; 5-formyl-2'-deoxyuridine; reductive amination; nucleoside Schiff bases; sodium triacetoxyborohydride

INTRODUCTION

Reductive amination of aldehydes and ketones is widely used in organic synthesis^[1] and provides expedient access to structurally diverse amines. In general, the reductive amination is a two-step transformation which proceeds via imine intermediate, further reduced to the corresponding amine by a variety of reducing agents, including NaBH_4 ,^[2] NaBH_3CN ,^[3] and $\text{NaBH}(\text{OAc})_3$.^[4–6]

Recently, reductive amination has found wide application in the synthesis of various modified nucleosides and nucleic acid conjugates.^[7] In particular, reductive amination of 5-formyl-2'-deoxyuridine (f^5dU) has been used in the synthesis of 5-alkylamino derivatives of pyrimidine nucleosides.^[8–11] These types of amino-modified nucleosides are useful units for nucleic acids labeling, stabilization of nucleic acids structures and for introduction of additional functionality to nucleic acid fragments designed as aptamers,


Received 31 March 2008; accepted 22 May 2008.

This work was supported by the State Committee for Scientific Research (Project PBZ-MNiSW-07/I/2007) and by European Social Fund and Polish State ("Mechanism WIDDOK" project, contract number Z/2.10/II/2.6/04/05/ U/2/06).

Address correspondence to Elzbieta Sochacka, Institute of Organic Chemistry, Technical University of Lodz, Zeromskiego 116, 90-924, Lodz, Poland. E-mail: ejsochac@p.lodz.pl

RESULTS AND DISCUSSION

After 4 hours at room temperature, TLC analysis (silica gel, CHCl₃/MeOH, 9:1 *v/v*) showed complete disappearance of starting nucleoside **1**, with no detectable reduction of 5-formyl group as compared with




SCHEME 1 Reductive amination of 5-formyl-5',3'-di-O-acetyl-2'-deoxyuridine (**1**) with RNH₂ **a–h** and NaBH(OAc)₃. *Reagents and conditions:* (i) 1.2 equivalent of RNH₂ **a–d** or (ii) 1.5 equivalent of RNH₂ **e–h**, and 2 hours for imine formation; (iii) for RNH₂ **a–d**—1.2 equivalent of NaBH(OAc)₃ and additional 0.5 equivalent after 2 hours, overall reaction time 4h or (iv) for RNH₂ **e–h**—1.2 equivalent of NaBH(OAc)₃ and additional 0.5 equivalent added after 2 hours and 4 hours, overall reaction time 16 hours.

authentic sample of 5-hydroxymethyl-3',5'-di-*O*-acetyl-2'-deoxyuridine.^[15] We observed formation of one product of low chromatographic mobility ($R_f = 0.16$, strong spot, UV lamp detection at 254 nm) and two more lipophilic compounds producing very weak TLC spots ($R_f = 0.44$ and $R_f = 0.55$). The latter products were better visualized with a ninhydrin test. The polar product was easily isolated by silica gel column chromatography in 44% yield and its spectral analysis (FAB MS, ^1H and ^{13}C NMR data) fully confirmed the structure of expected secondary amine derivative **3a**.

However, several attempts at chromatographic separation of two more lipophilic compounds were unsuccessful and they were isolated as a mixture in 48% yield. Spectral analysis of this mixture (FAB MS, ^1H , and ^{13}C NMR) revealed that these compounds are *Z* and *E* isomers of the 5-butylaminomethylidene-5,6-dihydro-3',5'-di-*O*-acetyl-2'-deoxyuridine **Z-4a** and **E-4a** (Scheme 1).

In the FAB MS, the measured m/z values for $[\text{M}+\text{H}]^+$ and $[\text{M}-\text{H}]^-$ were consistent with the MW calculated for **4a**. The UV spectrum of isomers **4a** (Figure 1) confirmed substantial changes in the structure of heterobase



derivative	line	λ_{max} (ϵ)	λ_{min}
1	—	290.5 (14000)	240.5
2a	- · -	295.5 (11200)	253.0
3a	·····	265.5 (8600)	243.5
Z and E 4a	- - -	308.5 (16500)	257.0

FIGURE 1 UV spectra of **1** and **2a–4a** in CHCl_3 , $c = 5.0 \times 10^{-5} \text{ mol/dm}^3$.

moiety as compared to **3a**. The values $\lambda_{\max} = 308.5$ nm and $\lambda_{\min} = 257.0$ nm explain poor visualization of TLC spots of **4a** under UV detection at 254 nm.

In a ^1H NMR spectrum recorded for the mixture of **4a** in the CDCl_3 solution, the shape of signals of H-1' anomeric protons revealed predominance of one isomer. The ratio of the isomers (80:20) and their *Z/E* configuration were determined by the analysis of the proton signals for characteristic $\text{C}=\text{CH}-\text{NH}$ fragment of the enamine **4a**. A doublet of higher intensity of a vinyl proton at 6.70 ppm compared to less intensive doublet of the more deshielded vinyl proton at 7.49 ppm indicated the *Z* configuration of the major isomer of **4a**. Additionally, a high chemical shift (8.37 ppm) of NH proton of major *Z* isomer may be explained in terms of intramolecular H-bonding between NH proton and oxygen atom of C-4 carbonyl group. Analogous NH signal of the minor *E* isomer was observed at 5.36 ppm. Both isomers showed a characteristic *trans*-vicinal coupling 13–14 Hz between the olefinic and the amino proton.

The formation of almost equal amounts of **3a** and **4a** can be explained by nonselective reduction of conjugated double bonds of Schiff base **2a** with $\text{NaBH}(\text{OAc})_3$. The secondary amine derivative **3a** is a 1,2-reduction product of **2a**, while isomers *Z/E*-**4a** result from unexpected 1,4-reduction of the imine derivative. It is worth to emphasize that the 5,6-dihydrouridines **4a** are non-aromatic compounds and therefore the process of 1,4-reduction should be rather not favorable. In particular, the 1,4-reductive amination products are not observed for various aromatic aldehydes under similar reductive amination conditions with $\text{NaBH}(\text{OAc})_3$.^[4–6] In the case of 5-formyl-2'-deoxyuridine **1**, the formation of 1,4-conjugated product is probably possible due to the stabilization of dihydrouridine derivative by intramolecular hydrogen bonding. Similar effect of the intramolecular H-bonding was observed for many compounds with analogous enamino functionality, for example, in the products derived from reactions of 3-formylchromones with amino compounds^[16] and for 6-aminomethylene derivatives of 5-oxo-2-phenyl-5,6,7,8-tetrahydroquinazoline.^[17]

Although the reduction with $\text{NaBH}(\text{OAc})_3$ is not selective toward conjugated double bond system of **2a**, it is worth to mention that the transformation of aldehyde **1** to amino-modified nucleosides **3** and **4** is almost quantitative. To the best of our knowledge, the dihydrouridine derivative of **4a** structure has not been described in the literature to date. In all the reported reactions of the reductive amination of f⁵dU, employing various amine components and NaBH_4 or NaBH_3CN , the secondary amine derivatives of 2'-deoxyuridines were the only isolated amino-modified products.^[6–10,14]

The scope of f⁵dU reductive amination carried out with $\text{NaBH}(\text{OAc})_3$ was investigated with a series of primary amines of different nucleophilicity

TABLE 1 Yields of secondary amine 2'-deoxyuridine derivatives **3** and 5,6-dihydro-2'-deoxyuridine derivatives **4** (*Z* and *E* isomers) in reductive amination of **1** with NaBH(OAc)₃

Entry	Amine	% of 3	% of 4 (<i>Z/E</i> ratio) ^a
a	<i>n</i> -butylamine	44	48 (80:20)
b	methylamine	39	56 (90:10)
c	histamine ^b	55	41 (85:15)
d	benzylamine	58	39 (55:45)
e	<i>t</i> -butylamine	7	85 (80:20)
f	aniline ^c	63	11 (70:30)
g	<i>p</i> -toluidine ^c	68	15 (90:10)
h	<i>p</i> -nitroaniline ^d	71	6 (90:10)

^aIsomers ratio was determined from the ¹H NMR spectra (CDCl₃) of isolated **4**.^bThe histamine derivative with MMTr on the imidazole ring was used as the amine component.^cUnreacted aldehyde **1** was isolated in 13% and 10% from the reaction mixture with aniline and *p*-toluidine, respectively.^d5-hydroxymethyl-3',5'-di-*O*-acetyl-2'-deoxyuridine was isolated in 17% yield (product of aldehyde **1** reduction).

(aliphatic and aromatic amines), steric hindrance (*t*-butylamine) and with additional functionality present (histamine; Table 1).

The reactions of ⁵dU **1** with reactive primary amines (Table 1, entries a through d) were performed following direct procedure with 1.2 molar excess of amine over aldehyde **1** and 1.7 molar equivalents of NaBH(OAc)₃ (1.2 equivalent of NaBH(OAc)₃ added directly after substrates mixing and additional 0.5 equivalent after 2 hours, Scheme 1). After 4 hours the substrate **1** was fully converted to the mixture of the corresponding products **3** and **4**, with no detectable aldehyde reduction. In experiments with *n*-butylamine and methylamine (entries a, b) the corresponding 5,6-dihydro-2'-deoxyuridine derivatives **4a** and **4b** were isolated in a slight excess over derivatives **3a** and **3b**, while for histamine and benzylamine (entries c, d) the yields of **3c** and **3d** were slightly higher than for **4c** and **4d**.

However, the predominant formation of dihydrouridine **4e** for bulky *t*-butylamine (entry e, 85% isolated yield of **4e** compared to 7% for **3e**) suggests the influence of steric factors associated with intermediate imine **2e** on the outcome of the reaction.

The reductive amination with weakly nucleophilic aromatic amines (Table 1, entries f through h) was performed according to a two-step preparative procedure with 1.5 molar excess of amine and 2 hours formation of intermediate imine. To each of the corresponding pre-formed Schiff bases **2f–h**, the 2.2 equivalents of NaBH(OAc)₃ were added in three portions (Scheme 1) and the reactions were continued for 16 hours. In the experiments with aniline and *p*-toluidine (entries f, g) the reduction

of intermediate imines with $\text{NaBH}(\text{OAc})_3$ was not completed and the unreacted **1** was isolated in ca. 10%. No competing aldehyde reduction was observed. In the case of the least basic *p*-nitroaniline the formation of imine **2h** was not quantitative and the product of aldehyde **1** reduction (5-hydroxymethyl-2'-deoxyuridine derivative) was isolated in 17% yield. In all experiments with aromatic amines, corresponding 5-arylaminoethyl-2'-deoxyuridines **3f-h** were isolated as the major products.

CONCLUSION

We have found that $\text{NaBH}(\text{OAc})_3$ is an efficient reducing agent towards the unique conjugate bond system of intermediate Schiff bases derived from 5-formyl-2'-deoxyuridine and various amines. In direct reductive amination of F^5dU with strong nucleophilic primary alkyl amines a quantitative conversion to amino-modified nucleosides was observed without any detectable amount of substrate aldehyde **1** reduction. For the non-hindered amine components, the reductive amination of **1** afforded nearly the same amounts of 1,2-reduction product **3** (2'-deoxyuridine derivatives) and of 1,4-reduction (**4**, 5,6-dihydro-2'-deoxyuridine analogs). For bulky *t*-butylamine, the predominant formation of the 5,6-dihydrouridine derivative (isolated yield 85%) indicates the influence of steric factors on the reduction process. In the reductive amination of aldehyde **1** with aromatic amines the corresponding secondary amine derivatives of 2'-deoxyuridine were isolated in good yields as the main reaction products. The new enamine analogs **4** are in fact nucleosides with vinylogous amide functionality which can explain their relatively high stability.

Our results expand the knowledge about reductive amination of F^5dU and may be useful in designing and synthesis of novel 5-amino-modified nucleosides for structural and biological activity studies.

EXPERIMENTAL

Representative Procedure for the Direct Reductive Amination of **1**; Reaction with *n*-Butylamine

5-Formyl-5',3'-di-O-acetyl-2'-deoxyuridine (**1**) (340 mg, 1 mmol) was dried by repeated co-evaporation with anhydrous CH_2Cl_2 (2×10 mL) and finally dissolved in the same solvent (7 mL). To this stirred solution, *n*-butylamine (118 μL , 1.2 mmol) was added followed by immediate addition of $\text{NaBH}(\text{OAc})_3$ (254 mg, 1.2 mmol). After 2 hours at room temperature, when TLC analysis ($\text{CHCl}_3/\text{MeOH}$ –9:1, v/v system) revealed some remaining aldehyde **1**, the second portion of $\text{NaBH}(\text{OAc})_3$ (106 mg, 0.5 mmol) was added. After stirring for an additional 2 hours, the reaction was quenched with NaHCO_3 (10 mL, 5% aq. solution) and then extracted with

CH_2Cl_2 (3×20 mL). The combined organic phases were dried (MgSO_4), filtered and concentrated in vacuo. The oily residue was chromatographed on a silica gel column with increasing amounts (from 0 to 25%) of CH_3OH in CHCl_3 . The corresponding fractions (checked on TLC with ninhydrine test) were collected and evaporated to give 5-*n*-butylaminomethylidene-5,6-dihydro-5',3'-di-*O*-acetyl-2'-deoxyuridine (**4a**) as a mixture of *Z* and *E* isomers (190 mg, yield 48%) and 5-*n*-butylaminomethyl-5',3'-di-*O*-acetyl-2'-deoxyuridine (**3a**) (175 mg, yield 44%).

TLC (silica gel plates): **3a** R_f 0.16 and **4a** R_f 0.44, 0.55 ($\text{CHCl}_3/\text{MeOH}$ 90:10); **3a** R_f 0.10 and **4a** R_f 0.37, 0.48 (AcOEt/MeOH 95:5).

Spectral Data for **3a** and **4a** *Z* and *E* Isomers

3a: m/z (HRMS, FAB) 398.1919 ($[\text{M}+\text{H}]^+$ $\text{C}_{18}\text{H}_{28}\text{N}_3\text{O}_7$ requires 398.1927); ^1H NMR (250 MHz, CDCl_3) δ 0.95 (t, 3H, $J = 7.3$ Hz, CH_3CH_2), 1.32–1.50 (m, 2H, $\text{CH}_3\text{CH}_2\text{CH}_2$), 1.58–1.80 (m, 2H, $\text{CH}_2\text{CH}_2\text{CH}_2$), 2.11 (s, 3H, CH_3COO), 2.15 (s, 3H, CH_3COO), 2.39 (ddd, 1H, $J_{\text{H}2',\text{H}3'} = 6.4$ Hz, $J_{\text{H}2',\text{H}1\text{v}} = 8.4$ Hz, $J_{\text{gem}} = 14.6$ Hz, $\text{H}2'$), 2.51 (ddd, 1H, $J_{\text{H}2'',\text{H}3'} = 2.0$ Hz, $J_{\text{H}2'',\text{H}1'} = 5.9$ Hz, $J_{\text{gem}} = 14.4$ Hz, $\text{H}2''$), 2.75–2.97 (m, 2H, $\text{CH}_2\text{CH}_2\text{NH}$), 3.67 (d, 1H, $J_{\text{gem}} = 13.1$ Hz, one of CH_2-7), 3.74 (d, 1H, $J_{\text{gem}} = 13.1$ Hz, one of CH_2-7), 4.22 (m, 1H, $\text{H}4'$), 4.30 (dd, 1H, $J_{\text{H}5'',\text{H}4'} = 3.7$ Hz, $J_{\text{gem}} = 11.9$ Hz, $\text{H}5''$), 4.45 (dd, 1H, $J_{\text{H}5',\text{H}4'} = 5.4$ Hz, $J_{\text{gem}} = 12.0$ Hz, $\text{H}5'$), 5.23 (dt, 1H, $J_{\text{H}3',\text{H}2''} = J_{\text{H}3',\text{H}4'} = 2.1$ Hz, $J_{\text{H}3',\text{H}2'} = 6.5$ Hz, $\text{H}3'$), 6.28 (dd, 1H, $J_{\text{H}1',\text{H}2''} = 5.8$ Hz, $J_{\text{H}1',\text{H}2'} = 8.3$ Hz, $\text{H}1'$), 7.83 (s, 1H, $\text{H}6$); ^{13}C NMR (63 MHz, CDCl_3) δ 13.68 (CH_3CH_2), 20.03 ($\text{CH}_3\text{CH}_2\text{CH}_2$), 20.89 (2x CH_3COO), 29.15 ($\text{CH}_2\text{CH}_2\text{CH}_2$), 36.91 ($\text{C}2'$), 44.31 ($\text{C}7$), 47.79 ($\text{CH}_2\text{CH}_2\text{NH}$), 63.85 ($\text{C}5'$), 74.29 ($\text{C}3'$), 82.49 ($\text{C}4'$), 85.42 ($\text{C}1'$), 107.57 ($\text{C}5$), 141.26 ($\text{C}6$), 150.54 ($\text{C}2$), 164.54 ($\text{C}4$), 170.31 (CH_3COO), 170.60 (CH_3COO); UV (CHCl_3) $\lambda_{\text{max}} = 265.5$ nm ($\epsilon = 8600$).

4a *Z* and *E* isomers; m/z (HRMS, FAB) 398.1938 ($[\text{M}+\text{H}]^+$ $\text{C}_{18}\text{H}_{28}\text{N}_3\text{O}_7$ requires 398.1927); ^1H NMR (250 MHz, CDCl_3) δ 0.94 (t, $J = 7.2$ Hz, 6H, CH_3CH_2 of *Z* and *E*), 1.24–1.47 (m, 4H, $\text{CH}_3\text{CH}_2\text{CH}_2$ of *Z* and *E*), 1.47–1.63 (m, 4H, $\text{CH}_2\text{CH}_2\text{CH}_2$ of *Z* and *E*), 1.98–2.26 (m, 16H, 2x CH_3COO , $\text{H}2'$, $\text{H}2''$ of *Z* and *E*), 3.20 (q, $J = 6.6$ Hz, 2H, $\text{CH}_2\text{CH}_2\text{NH}$ of *Z*), 3.28 (m, 1H, $\text{CH}_2\text{CH}_2\text{NH}$ of *E*), 3.53 (dd, $^4J_{\text{H}6,\text{H}7} = 1.4$ Hz, $J_{\text{gem}} = 13.2$ Hz, 1H, one of CH_2-6 of *E*), 3.75 (d, $J_{\text{gem}} = 12.6$ Hz, 1H, one of CH_2-6 of *Z*), 3.98 (d, $J_{\text{gem}} = 12.7$ Hz, 1H, one of CH_2-6 of *E*), 4.11 (m, 1H, $\text{H}4'$ of *Z*), 4.15–4.38 (m, 4H, $\text{H}5'$, $\text{H}5''$ of *Z*, $\text{H}4'$, $\text{H}5''$ of *E*), 4.52 (dd, $J_{\text{H}5',\text{H}4'} = 8.8$ Hz, $J_{\text{gem}} = 12.2$ Hz, 1H, $\text{H}5'$ of *E*), 5.02–5.18 (m, 2H, $\text{H}3'$ of *Z* and *E*), 5.36 (m, 1H, CH_2NHCH of *E*), 6.32 (dd, $J_{\text{H}1',\text{H}2''} = 6.1$ Hz, $J_{\text{H}1',\text{H}2'} = 8.7$ Hz, 1H, $\text{H}1'$ of *Z*), 6.41 (dd, $J_{\text{H}1',\text{H}2''} = 5.6$ Hz, $J_{\text{H}1',\text{H}2'} = 8.6$ Hz, 1H, $\text{H}1'$ of *E*), 6.70 (d, $J_{\text{H}7,\text{NH}} = 12.9$ Hz, 1H, $\text{H}7$ of *Z*), 7.10 (bs, 1H, $\text{NH}-3$ of *Z*), 7.14 (bs, 1H, $\text{NH}-3$ of *E*), 7.49 (d, $J_{\text{H}7,\text{NH}} = 13.1$ Hz, 1H, $\text{H}7$ of *E*), 8.37 (m, 1H, CH_2NHCH of *Z*); ^{13}C NMR (63 MHz, CDCl_3) δ 13.74

(CH₃CH₂ of *Z* and *E*), 19.70 (CH₃CH₂CH₂ of *E*), 19.76 (CH₃CH₂CH₂ of *E*), 20.98 (CH₃COO of *Z*), 21.05 (CH₃COO of *Z* and *E*) 21.22 (CH₃COO of *E*), 32.70 (C2' of *E*), 33.27 (CH₂CH₂CH₂ of *Z* and *E*, C2' of *Z*), 36.40 (C6 of *E*), 40.27 (C6 of *Z*), 48.88 (CH₂CH₂NH of *Z*), 49.04 (CH₂CH₂NH of *E*), 64.05 (C5' of *E*), 64.15 (C5' of *Z*), 74.36 (C3' of *Z* and *E*), 80.35 (C4' of *Z*), 81.14 (C4' of *E*), 84.18 (C1' of *Z*), 85.00 (C1' of *E*), 85.08 (C5 of *Z*), 87.34 (C5 of *E*), 146.70 (C7 of *E*), 149.95 (C7 of *Z*), 152.85 (C2 of *E*), 153.74 (C2 of *Z*), 165.05 (C4 of *E*), 166.98 (C4 of *Z*), 170.68 (2xCH₃COO of *Z*), 170.77 (CH₃COO- C3' of *E*), 171.62 (CH₃COO-C5' of *E*); UV (CHCl₃) λ_{max} = 308.5 nm (ε = 16500).

Direct Reductive Amination with Methylamine Hydrochloride

The same conditions were applied as for *n*-butylamine besides that methylamine hydrochloride was used and the free amine was obtained by the addition of equimolar amount of triethylamine.

Isolated products: **3b**, 138 mg, yield 39%; **4b**, 199 mg, yield 56%

TLC: **3b** R_f 0.06 and **4b** R_f 0.42, 0.58 (CHCl₃/MeOH 90:10); **3b** R_f 0.02 and **4b** R_f 0.29, 0.58 (AcOEt/MeOH 95:5).

Spectral Data for 3b and 4b Z and E Isomers

3b: *m/z* (HRMS, FAB) 356.1469 ([M+H]⁺ C₁₅H₂₂N₃O₇ requires 356.1458); ¹H NMR (250 MHz, CDCl₃) δ 2.11 (s, 3H, CH₃COO), 2.15 (s, 3H, CH₃COO), 2.27 (ddd, *J*_{H2',H3'} = 6.6 Hz, *J*_{H2',H1'} = 8.5 Hz, *J*_{gem} = 14.5 Hz, 1H, H2'), 2.43 (ddd, *J*_{H2'',H3'} = 1.9 Hz, *J*_{H2'',H1'} = 5.6 Hz, *J*_{gem} = 14.3 Hz, 1H, H2''), 2.52 (s, 3H, CH₃NH), 3.56 (d, *J*_{gem} = 13.6 Hz, 1H, one of CH₂-7), 3.63 (d, *J*_{gem} = 13.8 Hz, 1H, one of CH₂-7), 4.23 (m, 1H, H4'), 4.31 (dd, *J*_{H5',H4'} = 3.4 Hz, *J*_{gem} = 12.0 Hz, 1H, H5'), 4.41 (dd, *J*_{H5',H4'} = 4.8 Hz, *J*_{gem} = 12.0 Hz, 1H, H5'), 5.22 (dt, *J*_{H3',H2''} = *J*_{H3',H4'} = 2.0 Hz, *J*_{H3',H2'} = 6.7 Hz, 1H, H3'), 6.31 (dd, *J*_{H1',H2''} = 5.6 Hz, *J*_{H1',H2'} = 8.5 Hz, 1H, H1'), 7.66 (s, 1H, H6); ¹³C NMR (63 MHz, CDCl₃) δ 20.95 (CH₃COO), 21.05 (CH₃COO), 34.55 (CH₃NH), 37.34 (C2'), 47.13 (C7), 63.99 (C5'), 74.41 (C3'), 82.49 (C4'), 85.26 (C1'), 110.40 (C5'), 138.96 (C6), 150.75 (C2), 164.50 (C4), 170.52 (CH₃COO), 170.68 (CH₃COO); UV (CHCl₃) λ_{max} = 265 nm (ε = 8100).

4b *Z* and *E* isomers; *m/z* (HRMS, FAB) 356.1474 ([M+H]⁺ C₁₅H₂₂N₃O₇ requires 356.1458); ¹H NMR (250 MHz, CDCl₃) δ 2.10 (s, 3H, CH₃COO of *Z*), 2.11 (s, 3H, CH₃COO of *Z*), 2.11 (s, 3H, CH₃COO of *E*), 2.12 (s, 3H, CH₃COO of *E*), 2.00–2.28 (m, 4H, H2', H2'' of *Z* and *E*), 3.01 (d, *J* = 5.0 Hz, 3H, CH₃NH of *Z*), 3.07 (d, *J* = 4.7 Hz, 3H, CH₃NH of *E*), 3.66 (dd, ⁴*J*_{H6,H7} = 1.5 Hz, *J*_{gem} = 13.2 Hz, 1H, one of CH₂-6 of *E*), 3.79 (d, *J*_{gem} = 12.6 Hz, 1H, one of CH₂-6 of *Z*), 3.94 (d, *J*_{gem} = 12.5 Hz, 1H, one of CH₂-6 of *Z*), 3.98 (dd, ⁴*J*_{H6,H7} = 1.3 Hz, 1H, *J*_{gem} = 13.0 Hz, one of CH₂-6 of *E*), 4.06–4.28 (m, 5H, H4' of *Z* and *E*, H5', H5'' of *Z*, H5'' of *E*), 4.51

(dd, $J_{\text{H5}',\text{H4}'} = 8.8$ Hz, $J_{\text{gem}} = 12.2$ Hz, 1H, H5' of *E*), 5.05–5.14 (m, 2H, H3' of *Z* and *E*), 5.25 (m, 1H, CH_3NH of *E*), 6.32 (dd, $J_{\text{H1}',\text{H2}''} = 6.1$ Hz, $J_{\text{H1}',\text{H2}'} = 8.7$ Hz, 1H, H1' of *Z*), 6.40 (dd, $J_{\text{H1}',\text{H2}''} = 5.7$ Hz, $J_{\text{H1}',\text{H2}'} = 9.1$ Hz, 1H, H1' of *E*), 6.68 (d, $J_{\text{H7,NH}} = 13.1$ Hz, 1H, H7 of *Z*), 7.31 (s, 1H, *NH*-3 of *Z*), 7.34 (s, 1H, *NH*-3 of *E*), 7.45 (dt, $^4J_{\text{H7,H6}} = 1.3$ Hz, 1H, $J_{\text{H7,NH}} = 14.4$ Hz, H7 of *E*), 8.22 (m, 1H, CH_3NH of *Z*); ^{13}C NMR (63 MHz, CDCl_3) δ 21.04 (CH_3COO of *Z* and *E*), 21.10 (CH_3COO of *Z* and *E*), 33.40 (CH_3NH of *Z* and *E*), 35.37 (C2' of *Z* and *E*), 36.25 (C6 of *E*), 40.30 (C6 of *Z*), 64.10 (C5' of *E*), 64.21 (C5' of *Z*), 74.40 (C3' of *Z* and *E*), 80.43 (C4' of *Z*), 81.19 (C4' of *E*), 84.23 (C1' of *Z*), 85.05 (C1' of *E*), 85.59 (C5 of *Z*), 87.94 (C5 of *E*), 147.62 (C7 of *E*), 151.07 (C7 of *Z*), 152.80 (C2 of *E*), 153.64 (C2 of *Z*), 164.99 (C4 of *E*), 167.03 (C4 of *Z*), 170.71 (CH_3COO of *Z* and *E*), 170.79 (CH_3COO of *Z* and *E*); UV (CHCl_3) $\lambda_{\text{max}} = 305$ nm ($\epsilon = 13000$).

Direct Reductive Amination with Histamine Derivative

The histamine derivative with MMTr on the imidazole ring was prepared according to the procedure described by Verbeure, B., *at al.*^[18]

Isolated products: **3c**, 390 mg, yield 55%; **4c**, 290 mg, yield 41%.

TLC: **3c** R_f 0.32 and **4c** R_f 0.48, 0.63 ($\text{CHCl}_3/\text{MeOH}$ 90:10); **3c** R_f 0.11 and **4c** R_f 0.23, 0.41 (AcOEt/MeOH 90:10).

Spectral Data for **3c** and **4c Z** and **E** Isomers

3c: m/z (HRMS, FAB) 708.3052 ($[\text{M}+\text{H}]^+$ $\text{C}_{39}\text{H}_{42}\text{N}_5\text{O}_8$ requires 708.3033); ^1H NMR (250 MHz, CDCl_3) δ 2.10 (s, 3H, CH_3COO), 2.11 (s, 3H, CH_3COO), 2.30 (ddd, $J_{\text{H2}',\text{H3}'} = 6.4$ Hz, $J_{\text{H2}',\text{H1}'} = 8.4$ Hz, $J_{\text{gem}} = 14.5$ Hz, 1H, H2'), 2.43 (ddd, $J_{\text{H2}',\text{H3}'} = 1.8$ Hz, $J_{\text{H2}',\text{H1}'} = 5.7$ Hz, $J_{\text{gem}} = 14.3$ Hz, 1H, H2''), 2.80 (t, $J = 7.0$ Hz, 2H, ImCH_2), 2.99 (t, $J = 7.0$ Hz, 2H, CH_2NH), 3.57 (d, $J_{\text{gem}} = 13.7$ Hz, 1H, one of CH_2 -7), 3.66 (d, $J_{\text{gem}} = 13.8$ Hz, 1H, one of CH_2 -7), 3.81 (s, 3H, OCH_3), 4.21 (m, 1H, H4'), 4.28 (dd, $J_{\text{H5}',\text{H4}'} = 3.5$ Hz, $J_{\text{gem}} = 12.0$ Hz, 1H, H5''), 4.39 (dd, $J_{\text{H5}',\text{H4}'} = 4.7$ Hz, $J_{\text{gem}} = 12.0$ Hz, 1H, H5'), 5.22 (dt, $J_{\text{H3}',\text{H2}''} = J_{\text{H3}',\text{H4}'} = 2.0$ Hz, $J_{\text{H3}',\text{H2}'} = 6.3$ Hz, 1H, H3'), 6.30 (dd, $J_{\text{H1}',\text{H2}''} = 5.7$ Hz, $J_{\text{H1}',\text{H2}'} = 8.6$ Hz, 1H, H1'), 6.59 (d, $^4J_{\text{H5,H2}} = 1.2$ Hz, 1H, Im-CH-5), 6.77–7.37 (m, 14H, MMTr), 7.38 (d, $^4J_{\text{H2,H5}} = 1.4$ Hz, 1H, Im-CH-2), 7.66 (s, 1H, H6); ^{13}C NMR (63 MHz, CDCl_3) δ 21.08 (2x CH_3COO), 27.56 (ImCH_2), 37.34 (C2'), 45.52 (C7), 48.85 (CH_2NH), 55.47 (OCH_3), 64.03 (C5'), 74.58 (MMTr- CPh_3), 75.05 (C3'), 82.52 (C4'), 85.30 (C1'), 111.73 (C5), 113.45 (MMTr-o'), 118.74 (Im-CH-5), 128.19 (MMTr-o,p), 129.82 (MMTr-m), 131.30 (MMTr-m'), 134.64 (Im-CH-4), 138.13 (MMTr-i'), 138.64 (C6), 138.71 (Im-CH-2), 142.88 (MMTr-i), 150.43 (C2), 159.25 (MMTr-p'), 163.47 (C4), 170.51 (CH_3COO), 170.65 (CH_3COO); UV (CHCl_3) $\lambda_{\text{max}} = 266$ nm ($\epsilon = 7700$).

4c *Z* and *E* isomers; m/z (HRMS, FAB) 708.3048 ($[M+H]^+$ C₃₉H₄₂N₅O₈ requires 708.3033 ¹H NMR (250 MHz, CDCl₃) δ 2.08 (s, 3H, CH₃COO of *Z*), 2.09 (s, 3H, CH₃COO of *E*), 2.03–2.19 (m, 10H, 2xCH₃COO of *E*, H_{2'}, H_{2''} of *Z* and *E*), 2.77 (t, $J = 6.7$ Hz, 2H, ImCH₂ of *Z*), 2.79–2.88 (m, 2H, ImCH₂ of *E*), 3.48–3.60 (m, 4H, CH₂NH of *Z* and *E*), 3.81 (s, 3H, OCH₃ of *Z*), 3.82 (s, 3H, OCH₃ of *E*), 3.68–3.98 (m, 4H, CH₂–6 of *Z* and *E*), 3.99–4.39 (m, 6H, H_{4'}, H_{5'}, H_{5''} of *Z* and *E*), 5.06–5.19 (m, 3H, H_{3'} of *Z* and *E*, CH₂NHCH of *E*), 6.30 (dd, $J_{H1',H2''} = 5.9$ Hz, $J_{H1',H2'} = 8.9$ Hz, 1H, H_{1'} of *Z*), 6.41 (dd, $J_{H1',H2''} = 5.9$ Hz, $J_{H1',H2'} = 8.8$ Hz, 1H, H_{1'} of *E*), 6.60 (d, $^4J_{H5,H2} = 1.0$ Hz, 1H, Im-CH-5 of *Z*), 6.61 (d, $^4J_{H5,H2} = 1.0$ Hz, 1H, Im-CH-5 of *E*), 6.70 (d, $J_{H7,NH} = 13.1$ Hz, 1H, H₇ of *Z*), 6.79–7.41 (m, 31H, MMTr, NH-3 of *Z* and *E*, Im-CH-2 of *E*), 7.43 (d, $^4J_{H2,H5} = 1.3$ Hz, 1H, Im-CH-2 of *Z*), 7.46 (m, 1H, H₇ of *E*), 8.43 (m, 1H, CH₂NHCH of *Z*); ¹³C NMR (63 MHz, CDCl₃) δ 21.00 (CH₃COO of *E* and *Z*), 21.06 (CH₃COO of *E* and *Z*), 28.90 (ImCH₂ of *E*), 30.09 (ImCH₂ of *Z*), 32.69 (C_{2'} of *E*), 33.30 (C_{2'} of *Z*), 36.84 (C₆ of *E*), 40.32 (C₆ of *Z*), 48.75 (CH₂NH of *Z*), 49.34 (CH₂NH of *E*), 55.42 (OCH₃ of *Z* and *E*), 63.94 (C_{5'} of *E*), 64.16 (C_{5'} of *Z*), 74.34 (C_{3'} of *E*), 74.46 (C_{3'} of *Z*), 75.10 (MMTr-CPh₃ of *Z*), 75.22 (MMTr-CPh₃ of *E*), 80.44 (C_{4'} of *Z*), 80.66 (C_{4'} of *E*), 84.20 (C_{1'} of *Z*), 84.59 (C_{1'} of *E*), 85.00 (C₅ of *Z*), 87.43 (C₅ of *E*), 113.44 (MMTr-o' of *Z* and *E*), 118.91 (Im-CH-5 of *E*), 119.60 (Im-CH-5 of *Z*), 128.17 (MMTr-o of *Z* and *E*, MMTr-p of *Z*), 128.44 (MMTr-p of *E*), 129.74 (MMTr-m of *Z* and *E*), 131.23 (131.30 (MMTr-m' of *Z* and *E*), 134.31 (Im-CH-4 of *E*), 134.43 (Im-CH-4 of *Z*), 137.18 (MMTr-i' of *Z*), 137.75 (MMTr-i' of *E*), 138.57 (Im-CH-2 of *E*), 138.83 (Im-CH-2 of *Z*), 142.61 (MMTr-i of *E*), 142.70 (MMTr-i of *Z*), 146.72 (C₇ of *E*), 150.15 (C₇ of *Z*), 153.09 (C₂ of *E*), 153.81 (C₂ of *Z*), 159.25 (MMTr-p' of *Z* and *E*), 164.91 (C₄ of *E*), 166.71 (C₄ of *Z*), 170.63 (CH₃COO of *Z* and *E*), 171.09 (CH₃COO of *Z* and *E*); UV (CHCl₃) $\lambda_{\max} = 305$ nm ($\epsilon = 12600$).

Direct Reductive Amination with Benzylamine

Isolated products: **3d**, 250 mg, yield 58%; **4d**, 168 mg, yield 39%.

TLC: **3d** R_f 0.23 and **4d** R_f 0.30, 0.49 (CHCl₃/MeOH 95:5); **3d** R_f 0.25 and **4d** R_f 0.30, 0.56 (AcOEt/MeOH 95:5).

Spectral Data for **3d** and **4d** *Z* and *E* Isomers

3d: m/z (HRMS, FAB) 432.1764 ($[M+H]^+$ C₂₁H₂₆N₃O₇ requires 432.1771); ¹H NMR (250 MHz, CDCl₃) δ 1.98 (s, 3H, CH₃COO), 2.11 (s, 3H, CH₃COO), 2.17 (m, 1H, H_{2'}), 2.45 (ddd, $J_{H2'',H3'} = 1.8$ Hz, $J_{H2'',H1'} = 5.6$ Hz, $J_{\text{gem}} = 14.1$ Hz, 1H, H_{2''}), 3.52 (s, 2H, CH₂–7), 3.80 (s, 2H, PhCH₂), 4.20–4.32 (m, 2H, H_{4'}, H_{5''}), 4.38 (dd, $J_{H5',H4'} = 4.0$ Hz, $J_{\text{gem}} = 11.8$ Hz, 1H, H_{5'}), 5.20 (dt, $J_{H3',H2''} = J_{H3',H4'} = 1.8$ Hz, $J_{H3',H2'} = 6.5$ Hz, 1H, H_{3'}), 6.33 (dd, $J_{H1',H2''} = 5.5$ Hz, $J_{H1',H2'} = 8.6$ Hz, 1H, H_{1'}), 7.18–7.38 (m, 6H,

Ph), 7.46 (s, 1H, H6); ^{13}C NMR (63 MHz, CDCl_3) δ 20.82 (CH_3COO), 21.05 (CH_3COO), 37.62 ($\text{C}2'$), 45.62 ($\text{C}7$), 53.21 (PhCH_2), 64.01 ($\text{C}5'$), 74.37 ($\text{C}3'$), 82.36 ($\text{C}4'$), 85.04 ($\text{C}1'$), 113.61 ($\text{C}5$), 127.33 (Ph-p), 128.35 (Ph-m), 128.65 (Ph-o), 136.42 ($\text{C}6$), 139.61 (Ph-i), 150.51 ($\text{C}2$), 163.52 ($\text{C}4$), 170.46 (CH_3COO), 170.54 (CH_3COO); UV (CHCl_3) $\lambda_{\text{max}} = 264 \text{ nm}$ ($\epsilon = 8200$).

4d *Z* and *E* isomers; m/z (HRMS, FAB) 432.1755 ($[\text{M}+\text{H}]^+$ $\text{C}_{21}\text{H}_{26}\text{N}_3\text{O}_7$ requires 432.1771); ^1H NMR (250 MHz, CDCl_3) δ 2.05 (s, 3H, CH_3COO of *Z*), 2.09 (s, 3H, CH_3COO of *Z*), 1.94–2.39 (m, 10H, $2\times\text{CH}_3\text{COO}$ of *E*, $\text{H}2'$, $\text{H}2''$ of *Z* and *E*), 3.67 (dd, $^4J_{\text{H}6,\text{H}7} = 1.8 \text{ Hz}$, $J_{\text{gem}} = 13.2 \text{ Hz}$, 1H, one of CH_2 -6 of *E*), 3.79 (d, $J_{\text{gem}} = 12.8 \text{ Hz}$, 1H, one of CH_2 -6 of *Z*), 3.95 (d, $J_{\text{gem}} = 12.8 \text{ Hz}$, 1H, one of CH_2 -6 of *Z*), 4.01 (m, 1H, one of CH_2 -6 of *E*), 4.10 (m, 1H, $\text{H}4'$ of *Z*), 4.21–4.56 (m, 5H, $\text{H}5'$, $\text{H}5''$ of *Z* and *E*, $\text{H}4'$ of *E*), 4.39 (d, $J = 5.9 \text{ Hz}$, 2H, PhCH_2NH of *Z*), 4.44 (d, $J = 5.8 \text{ Hz}$, 1H, PhCH_2NH of *E*), 5.03–5.14 (m, 2H, $\text{H}3'$ of *Z* and *E*), 5.75 (m, 1H, CH_2NHCH of *E*), 6.32 (dd, $J_{\text{H}1',\text{H}2''} = 6.1 \text{ Hz}$, $J_{\text{H}1',\text{H}2'} = 8.7 \text{ Hz}$, 1H, $\text{H}1'$ of *Z*), 6.40 (dd, $J_{\text{H}1',\text{H}2''} = 5.6 \text{ Hz}$, $J_{\text{H}1',\text{H}2'} = 9.5 \text{ Hz}$, 1H, $\text{H}1'$ of *E*), 6.76 (d, $J_{\text{H}7,\text{NH}} = 12.9 \text{ Hz}$, 1H, $\text{H}7$ of *Z*), 7.11–7.46 (m, 12H, Ph, NH -3 of *Z* and *E*), 7.60 (dt, $^4J_{\text{H}7,\text{H}6} = 1.4 \text{ Hz}$, $J_{\text{H}7,\text{NH}} = 14.3 \text{ Hz}$, 1H, $\text{H}7$ of *E*), 8.68 (m, 1H, CH_2NHCH of *Z*); ^{13}C NMR (63 MHz, CDCl_3) δ 20.99 ($2\times\text{CH}_3\text{COO}$ of *E*), 21.10 ($2\times\text{CH}_3\text{COO}$ of *Z*), 32.71 ($\text{C}2'$ of *E*), 33.37 ($\text{C}2'$ of *Z*), 36.42 ($\text{C}6$ of *E*), 40.32 ($\text{C}6$ of *Z*), 52.48 (PhCH_2 of *Z*), 53.19 (PhCH_2 of *E*), 64.05 ($\text{C}5'$ of *E*), 64.16 ($\text{C}5'$ of *Z*), 74.37 ($\text{C}3'$ of *Z* and *E*), 80.45 ($\text{C}4'$ of *Z*), 81.32 ($\text{C}4'$ of *E*), 84.24 ($\text{C}1'$ of *Z*), 85.13 ($\text{C}1'$ of *E*), 86.54 ($\text{C}5$ of *Z*), 88.48 ($\text{C}5$ of *E*), 127.41 (Ph-o of *Z*), 127.73 (Ph-o of *E*), 128.02 (Ph-p of *E*), 128.12 (Ph-p of *E*), 129.03 (Ph-m of *Z* and *E*), 137.87 (Ph-i of *E*), 138.07 (Ph-i of *Z*), 146.35 ($\text{C}7$ of *E*), 149.54 ($\text{C}7$ of *Z*), 152.67 ($\text{C}2$ of *E*), 153.55 ($\text{C}2$ of *Z*), 165.00 ($\text{C}4$ of *E*), 166.96 ($\text{C}4$ of *Z*), 170.69 (CH_3COO of *Z* and *E*), 170.77 (CH_3COO of *Z* and *E*); UV (CHCl_3) $\lambda_{\text{max}} = 304.5 \text{ nm}$ ($\epsilon = 14600$).

Representative Procedure for the Undirect Reductive Amination of **1**; Reaction with *t*-Butylamine

5-Formyl-5',3'-di-O-acetyl-2'-deoxyuridine (**1**) (340 mg, 1 mmol), predried by repeated evaporation with anhydrous CH_2Cl_2 ($2 \times 10 \text{ mL}$), was dissolved in the same solvent (7 mL) and *t*-butylamine (158 μL , 1.5 mmol) was added. The reaction mixture was stirred for 2 hours at room temperature and then treated with $\text{NaBH}(\text{OAc})_3$ (254 mg, 1.2 mmol). After 2 and 4 hours, when TLC analysis ($\text{CHCl}_3/\text{MeOH}$ –95:5, v/v system) revealed some remaining aldehyde **1**, two additional portions of $\text{NaBH}(\text{OAc})_3$ (each 106 mg, 0.5 mmol) were added. After stirring for the next 12 hours, the reaction was quenched with NaHCO_3 (10 mL, 5% aq. solution) and then extracted with CH_2Cl_2 ($3 \times 20 \text{ mL}$). The combined organic phases were dried over MgSO_4 , filtered and concentrated in vacuo. The oily residue was purified on

a silica gel column using increasing amounts of CH₃OH in CHCl₃ (from 0 to 25%). The corresponding fractions (checked on TLC with ninhydrine test) were collected and evaporated to give 5-*t*-butylaminomethylidene-5,6-dihydro-5',3'-di-*O*-acetyl-2'-deoxyuridine (**4e**) as a mixture of *Z* and *E* isomers (337 mg, yield 85%) and 5-*t*-butylaminomethyl-5',3'-di-*O*-acetyl-2'-deoxyuridine (**3e**) (28 mg, yield 7%).

TLC: **3e** R_f 0.09 and **4e** R_f 0.20, 0.28 in (CHCl₃/MeOH 95:5); **3e** R_f 0.03 and **4e** R_f 0.28, 0.58 (AcOEt/MeOH 95:5).

Spectral Data for **3e** and **4e** *Z* and *E* Isomers

3e: *m/z* (HRMS, FAB) 398.1909 ([M+H]⁺ C₁₈H₂₈N₃O₇ requires 398.1927); ¹H NMR (250 MHz, CDCl₃) δ 1.43 (s, 9H, (CH₃)₃C), 2.11 (s, 3H, CH₃COO), 2.20 (s, 3H, CH₃COO), 2.50–2.73 (m, 2H, H2', H2''), 3.63 (d, *J*_{gem} = 12.5 Hz, 1H, one of CH₂-7), 3.82 (d, *J*_{gem} = 12.3 Hz, 1H, one of CH₂-7), 4.20 (ddd, *J*_{H4',H3'} = 2.0 Hz, *J*_{H4',H5''} = 3.3 Hz, *J*_{H4',H5'} = 5.5 Hz, 1H, H4'), 4.29 (dd, *J*_{H5'',H4'} = 3.4 Hz, *J*_{gem} = 12.0 Hz, 1H, H5''), 4.55 (dd, *J*_{H5',H4'} = 5.5 Hz, *J*_{gem} = 11.9 Hz, 1H, H5'), 5.26 (m, 1H, H3'), 6.31 (m, 1H, H1'), 7.98 (s, 1H, H6);

¹³C NMR (63 MHz, CDCl₃) δ 21.12 (CH₃COO), 21.30 (CH₃COO), 26.76 ((CH₃)₃C), 37.04 (C2'), 38.57 (C7), 55.87 ((CH₃)₃C), 64.19 (C5'), 74.85 (C3'), 83.36 (C4'), 85.88 (C1'), 105.11 (C5), 144.06 (C6), 149.70 (C2), 164.82 (C4), 170.57 (CH₃COO), 170.98 (CH₃COO); UV (CHCl₃) λ_{max} = 266 nm (ε = 7900).

4e *Z* and *E* isomers; *m/z* (HRMS, FAB) 398.1919 ([M+H]⁺ C₁₈H₂₈N₃O₇ requires 398.1927); ¹H NMR (250 MHz, CDCl₃) δ 1.31 (s, 18H, (CH₃)₃C of *Z*), 1.34 (s, 3H, (CH₃)₃C of *E*), 2.10 (s, 3H, CH₃COO of *Z*), 2.11 (m, 3H, CH₃COO of *Z*), 2.12 (m, 3H, CH₃COO of *E*), 2.13 (s, 3H, CH₃COO of *E*), 2.01–2.31 (m, 4H, H2', H2'' of *Z* and *E*), 3.64 (dd, ⁴*J*_{H6,H7} = 1.6 Hz, *J*_{gem} = 13.2 Hz, 1H, one of CH₂-6 of *E*), 3.80 (dd, ⁴*J*_{H6,H7} = 0.8 Hz, *J*_{gem} = 12.6 Hz, 1H, one of CH₂-6 of *Z*), 3.96 (dd, ⁴*J*_{H6,H7} = 0.8 Hz, *J*_{gem} = 12.6 Hz, 1H, one of CH₂-6 of *Z*), 4.00 (dd, ⁴*J*_{H6,H7} = 1.4 Hz, *J*_{gem} = 13.3 Hz, 1H, one of CH₂-6 of *E*), 4.11 (m, 1H, H4' of *Z*), 4.16–4.44 (m, 4H, H5', H5'' of *Z*, H4', H5'' of *E*), 4.53 (dd, *J*_{H5',H4'} = 1.8 Hz, *J*_{gem} = 9.1 Hz, 1H, H5' of *E*), 5.02–5.18 (m, 2H, H3' of *Z* and *E*), 5.45 (d, *J*_{NH,H7} = 15.0 Hz, 1H, CNHCH of *E*), 6.34 (dd, *J*_{H1',H2''} = 6.0 Hz, *J*_{H1',H2'} = 8.8 Hz, 1H, H1' of *Z*), 6.41 (dd, *J*_{H1',H2''} = 5.6 Hz, *J*_{H1',H2'} = 9.2 Hz, 1H, H1' of *E*), 6.88 (d, *J*_{H7,NH} = 13.6 Hz, 1H, H7 of *Z*), 7.16 (bs, 1H, NH-3 of *Z*), 7.20 (s, 1H, NH-3 of *E*), 7.68 (dt, *J*_{H7,H6} = 1.5 Hz, *J*_{H7,NH} = 15.0 Hz, 1H, H7 of *E*), 8.65 (d, *J*_{NH,H7} = 13.6 Hz, 1H, CNHCH of *Z*); ¹³C NMR (63 MHz, CDCl₃) δ 21.02 (2xCH₃COO of *Z*), 21.10 (2xCH₃COO of *E*), 30.27 ((CH₃)₃C of *Z* and *E*), 32.72 (C2' of *E*), 33.28 (C2' of *Z*), 36.44 (C6 of *E*), 40.58 (C6 of *Z*), 52.32 ((CH₃)₃C of *Z*), 53.22 ((CH₃)₃C of *E*), 64.00 (C5' of *E*), 64.14 (C5' of *Z*), 74.36 (C3' of *Z*), 74.47 (C3' of *E*), 80.40 (C4' of *Z*), 81.44 (C4' of *E*), 84.25 (C1' of *Z*), 84.98

(C5 of *Z*), 85.19 (C1' of *E*), 87.55 (C5 of *E*), 142.31 (C7 of *E*), 145.65 (C7 of *Z*), 152.69 (C2 of *E*), 153.73 (C2 of *Z*), 164.80 (C4 of *E*), 166.72 (C4 of *Z*), 170.71, 170.80, 171.45 (2xCH₃COO of *Z* and *E*); UV (CHCl₃) λ_{max} = 305 nm (ε = 16200).

Undirect Reductive Amination with Aniline

Isolated products: **3f**, 263 mg, yield 63%; **4f**, 46 mg, yield 11%.

TLC: **3f** R_f 0.20 and **4f** R_f 0.41, 0.49 (CHCl₃/MeOH 95:5); **3f** R_f 0.60 and **4f** R_f 0.55, 0.72 (AcOEt/MeOH 95:5).

Spectral Data for **3f** and **4f** *Z* and *E* Isomers

3f: *m/z* (HRMS, FAB) 418.1624 ([M+H]⁺ C₂₀H₂₄N₃O₇ requires 418.1614) ¹H NMR (250 MHz, CDCl₃) δ 2.02 (m, 1H, H_{2'}), 2.05 (s, 3H, CH₃COO), 2.10 (s, 3H, CH₃COO), 2.43 (ddd, *J*_{H_{2''},H_{3'}} = 1.8 Hz, *J*_{H_{2''},H_{1'}} = 5.6 Hz, *J*_{gem} = 14.3 Hz, 1H, H_{2''}), 4.04–4.16 (m, 3H, CH₂–7, H_{5''}), 4.19 (m, 1H, H_{4'}), 4.27 (dd, *J*_{H_{5'},H_{4'}} = 4.9 Hz, *J*_{gem} = 11.2 Hz, 1H, H_{5'}), 5.11 (dt, *J*_{H_{3'},H_{2''}} = *J*_{H_{3'},H_{4'}} = 1.9 Hz, *J*_{H_{3'},H_{2'}} = 6.4 Hz, 1H, H_{3'}), 6.28 (dd, *J*_{H_{1'},H_{2''}} = 5.5 Hz, *J*_{H_{1'},H_{2'}} = 8.6 Hz, 1H, H_{1'}), 6.58–6.65 (m, 2H, Ph-o), 6.73 (m, 1H, Ph-p), 7.12–7.22 (m, 2H, Ph-m), 7.44 (t, ⁴*J*_{H₆,H₇} = 1.2 Hz, 1H, H₆);

¹³C NMR (63 MHz, CDCl₃) δ 20.83 (CH₃COO), 20.97 (CH₃COO), 37.48 (C_{2'}), 41.03 (C₇), 63.80 (C_{5'}), 74.25 (C_{3'}), 82.40 (C_{4'}), 85.31 (C_{1'}), 112.51 (C₅), 113.52 (Ph-o), 118.36 (Ph-p), 129.42 (Ph-m), 136.19 (C₆), 147.39 (Ph-i), 150.44 (C₂), 163.50 (C₄), 170.48 (CH₃COO), 170.67 (CH₃COO); UV(MeOH) λ_{max} = 248 nm (ε = 11000).

4f *Z* and *E* isomers; *m/z* (HRMS, FAB) 418.1629 ([M+H]⁺ C₂₀H₂₄N₃O₇ requires 418.1614) ¹H NMR (250 MHz, CDCl₃) δ 2.10 (s, 3H, CH₃COO of *Z*), 2.12 (s, 3H, CH₃COO of *Z*), 2.03–2.31 (m, 10H, 2xCH₃COO of *E*, H_{2'}, H_{2''} of *Z* and *E*), 3.81 (dd, ⁴*J*_{H₆,H₇} = 1.9 Hz, *J*_{gem} = 13.9 Hz, 1H, one of CH₂–6 of *E*), 3.92 (dd, ⁴*J*_{H₆,H₇} = 0.7 Hz, *J*_{gem} = 13.1 Hz, 1H, one of CH₂–6 of *Z*), 4.04–4.40 (m, 7H, one of CH₂–6, H_{4'} of *Z* and *E*, H_{5'}, H_{5''} of *Z*, H_{5''} of *E*), 4.69 (dd, *J*_{H_{5'},H_{4'}} = 9.5 Hz, *J*_{gem} = 12.1 Hz, 1H, H_{5'} of *E*), 5.08–5.18 (m, 2H, H_{3'} of *Z* and *E*), 5.21 (m, 1H, PhNHCH of *E*), 6.34 (dd, *J* = 6.1 Hz, *J* = 8.6 Hz, 1H, H_{1'} of *Z*), 6.42 (dd, *J*_{H_{1'},H_{2''}} = 5.2 Hz, *J*_{H_{1'},H_{2'}} = 9.6 Hz, 1H, H_{1'} of *E*), 6.54–7.48 (m, 13H, Ph, NH-3 of *Z* and *E*, H₇ of *Z*), 8.06 (dt, ⁴*J*_{H₇,H₆} = 1.7 Hz, *J*_{H₇,NH} = 13.8 Hz, 1H, H₇ of *E*), 10.29 (d, *J*_{NH,H₇} = 12.6 Hz, 1H, PhNHCH of *Z*); ¹³C NMR (63 MHz, CDCl₃) δ, 20.93 (CH₃COO of *E* and *Z*), 21.09 (CH₃COO of *E* and *Z*), 32.90 (C_{2'} of *E*), 33.45 (C_{2'} of *Z*), 36.38 (C₆ of *E*), 40.35 (C₆ of *Z*), 64.10 (C_{5'} of *Z* and *E*), 74.38 (C_{3'} of *Z* and *E*), 80.70 (C_{4'} of *Z*), 81.73 (C_{4'} of *E*), 84.42 (C_{1'} of *Z*), 85.38 (C_{1'} of *E*), 89.92 (C₅ of *Z*), 92.50 (C₅ of *E*), 115.85 (Ph-o of *E*), 115.98 (Ph-o of *Z*), 130.27 (Ph-m of *E*), 130.35 (Ph-m of *Z*), 131.68 (Ph-p of *E*), 132.01 (Ph-p of *Z*), 137.65 (C₇ of *E*), 138.53 (Ph-i of *Z*), 139.41 (Ph-i of *E*), 141.02 (C₇ of *Z*), 152.44 (C₂ of *E*), 153.25 (C₂ of *Z*), 165.03 (C₄ of *E*), 166.99 (C₄ of *Z*),

170.66 (CH_3COO of *Z* and *E*), 170.74, (CH_3COO of *Z* and *E*); UV(MeOH) $\lambda_{\text{max}} = 340.5 \text{ nm}$ ($\epsilon = 20600$).

Undirect Reductive Amination with *p*-Toluidine

Isolated products: **3g**, 293 mg, yield 68%; **4g**, 65 mg, yield 15%.

TLC: **3g** R_f 0.24 and **4g** R_f 0.28, 0.47 in ($\text{CHCl}_3/\text{MeOH}$ 95:5); **3g** R_f 0.15 and **4g** R_f 0.23, 0.46 (AcOEt/MeOH 98:2).

Spectral Data for **3g** and **4g** *Z* and *E* Isomers

3g: m/z (HRMS, FAB) 432.1784 ($[\text{M}+\text{H}]^+$ $\text{C}_{21}\text{H}_{26}\text{N}_3\text{O}_7$ requires 432.1771); ^1H NMR (250 MHz, CDCl_3) δ 2.03 (m, 1H, H_2'), 2.05 (s, 3H, CH_3COO), 2.10 (s, 3H, CH_3COO), 2.22 (s, 3H, CH_3Ph), 2.43 (ddd, $J_{\text{H}_2'',\text{H}_3'} = 1.8 \text{ Hz}$, $J_{\text{H}_2'',\text{H}_1'} = 5.6 \text{ Hz}$, $J_{\text{gem}} = 14.2 \text{ Hz}$, 1H, H_2''), 4.00–4.17 (m, 3H, CH_2 –7, H_5''), 4.19 (m, 1H, H_4'), 4.27 (dd, $J_{\text{H}_5',\text{H}_4'} = 4.6 \text{ Hz}$, $J_{\text{gem}} = 11.2 \text{ Hz}$, 1H, H_5'), 5.11 (dt, $J_{\text{H}_3',\text{H}_2''} = J_{\text{H}_3',\text{H}_4'} = 1.6 \text{ Hz}$, $J_{\text{H}_3',\text{H}_2'} = 6.3 \text{ Hz}$, 1H, H_3'), 6.27 (dd, $J_{\text{H}_1',\text{H}_2''} = 5.6 \text{ Hz}$, $J_{\text{H}_1',\text{H}_2'} = 8.6 \text{ Hz}$, 1H, H_1'), 6.44–6.64 (m, 2H, Ph-o), 6.83–7.07 (m, 2H, Ph-m), 7.43 (t, $^4J_{\text{H}_6,\text{H}_7} = 1.1 \text{ Hz}$, 1H, H_6); ^{13}C NMR (63 MHz, CDCl_3) δ 20.43 (CH_3COO), 20.79 (CH_3COO), 20.94 (CH_3Ph), 37.45 (C_2'), 41.46 (C_7), 63.79 (C_5'), 74.26 (C_3'), 82.35 (C_4'), 85.26 (C_1'), 112.64 (C_5), 113.80 (Ph-o), 127.65 (Ph-p), 129.88 (Ph-m), 136.18 (C_6), 145.00 (Ph-i), 150.45 (C_2), 163.48 (C_4), 170.46 (CH_3COO), 170.48 (CH_3COO); UV(MeOH) $\lambda_{\text{max}} = 247 \text{ nm}$ ($\epsilon = 12300$).

4g *Z* and *E* isomers; m/z (HRMS, FAB) 432.1765 ($[\text{M}+\text{H}]^+$ $\text{C}_{21}\text{H}_{26}\text{N}_3\text{O}_7$ requires 432.1771); ^1H NMR (250 MHz, CDCl_3) δ 2.11 (s, 3H, CH_3COO of *Z*), 2.12 (s, 3H, CH_3COO of *Z*), 2.06–2.41 (m, 13H, $2\times\text{CH}_3\text{COO}$, CH_3Ph of *E*, H_2' , H_2'' of *Z* and *E*), 2.31 (s, 3H, CH_3Ph of *Z*), 3.81 (dd, $^4J_{\text{H}_6,\text{H}_7} = 1.8 \text{ Hz}$, $J_{\text{gem}} = 13.9 \text{ Hz}$, 1H, one of CH_2 –6 of *E*), 3.92 (d, $J_{\text{gem}} = 13.6 \text{ Hz}$, 1H, one of CH_2 –6 of *Z*), 4.04–4.18 (m, 3H, one of CH_2 –6 of *Z* and *E*, H_4' of *Z*), 4.19–4.41 (m, 4H, H_5' , H_5'' of *Z*, H_4' , H_5'' of *E*), 4.70 (dd, $J_{\text{H}_5',\text{H}_4'} = 9.4 \text{ Hz}$, $J_{\text{gem}} = 12.1 \text{ Hz}$, 1H, H_5' of *E*), 5.09–5.17 (m, 2H, H_3' of *Z* and *E*), 5.21 (m, 1H, PhNHCH of *E*), 6.34 (dd, $J_{\text{H}_1',\text{H}_2''} = 6.1 \text{ Hz}$, $J_{\text{H}_1',\text{H}_2'} = 8.7 \text{ Hz}$, 1H, H_1' of *Z*), 6.41 (dd, $J_{\text{H}_1',\text{H}_2''} = 5.0 \text{ Hz}$, $J_{\text{H}_1',\text{H}_2'} = 9.3 \text{ Hz}$, 1H, H_1' of *E*), 6.86–7.47 (m, 10H, Ph, NH-3 of *Z* and *E*), 7.31 (d, $J_{\text{H}_7,\text{NH}} = 12.7 \text{ Hz}$, 1H, H_7 of *Z*), 8.03 (m, 1H, H_7 of *E*), 10.24 (d, $J_{\text{NH},\text{H}_7} = 12.6 \text{ Hz}$, 1H, PhNHCH of *Z*); ^{13}C NMR (63 MHz, CDCl_3) δ , 20.81 (CH_3Ph), 21.07 ($2\times\text{CH}_3\text{COO}$ of *E* and *Z*), 32.85 (C_2' of *E*), 33.43 (C_2' of *Z*), 36.44 (C_6 of *E*), 40.40 (C_6 of *Z*), 64.11 (C_5' of *Z* and *E*), 74.34 (C_3' of *Z*), 74.45 (C_3' of *E*), 80.62 (C_4' of *Z*), 81.60 (C_4' of *E*), 84.33 (C_1' of *Z*), 85.35 (C_1' of *E*), 89.86 (C_5 of *Z*), 92.47 (C_5 of *E*), 115.89 (Ph-o of *E*), 116.05 (Ph-o of *Z*), 130.31 (Ph-m of *E*), 130.39 (Ph-m of *Z*), 132.89 (Ph-p of *E*), 133.22 (Ph-p of *Z*), 137.81 (C_7 of *E*), 137.96 (Ph-i of *Z*), 138.52 (Ph-i of *E*), 141.22 (C_7 of *Z*), 152.47 (C_2 of *E*), 153.27 (C_2 of *Z*), 164.99 (C_4 of *E*), 166.96 (C_4 of *Z*), 170.68 (CH_3COO

of *Z* and *E*), 170.76, (CH_3COO of *Z* and *E*); UV(MeOH) $\lambda_{\text{max}} = 340$ nm ($\varepsilon = 21000$).

Undirect Reductive Amination with *p*-Nitroaniline

Isolated products: **3h**, 254 mg, yield 55%; **4h**, 28 mg, yield 6%

TLC : **3h** R_f 0.23 and **4h** R_f 0.43, 0.53 in ($\text{CHCl}_3/\text{MeOH}$ 95:5); **3h** R_f 0.10 and **4h** R_f 0.23, 0.44 (AcOEt/MeOH 98:2).

Spectral Data for **3h** and **4h** *Z* and *E* Isomers

3h: m/z (HRMS, FAB) 463.1452 ($[\text{M}+\text{H}]^+$ $\text{C}_{20}\text{H}_{23}\text{N}_4\text{O}_9$ requires 463.1465) ^1H NMR (250 MHz, CDCl_3) δ 2.04 (m, 1H, $\text{H}2'$), 2.10 (s, 3H, CH_3COO), 2.12 (s, 3H, CH_3COO), 2.53 (ddd, $J_{\text{H}2'',\text{H}3'} = 1.8$ Hz, $J_{\text{H}2'',\text{H}1'} = 5.5$ Hz, $J_{\text{gem}} = 14.3$ Hz, 1H, $\text{H}2''$), 4.16–4.52 (m, 5H, CH_2 –7, $\text{H}4'$, $\text{H}5'$, $\text{H}5''$), 5.13 (dt, $J_{\text{H}3',\text{H}2''} = J_{\text{H}3',\text{H}4'} = 2.0$ Hz, $J_{\text{H}3',\text{H}2'} = 6.6$ Hz, 1H, $\text{H}3'$), 6.24 (dd, $J_{\text{H}1',\text{H}2''} = 5.4$ Hz, $J_{\text{H}1',\text{H}2'} = 8.4$ Hz, 1H, $\text{H}1'$), 6.60–6.74 (m, 2H, Ph-o), 7.59 (s, 1H, H6), 8.03–8.14 (m, 2H, Ph-m); ^{13}C NMR (63 MHz, CDCl_3) δ 20.97 ($2\times\text{CH}_3\text{COO}$), 37.69 ($\text{C}2'$), 40.16 ($\text{C}7$), 63.78 ($\text{C}5'$), 74.07 ($\text{C}3'$), 82.78 ($\text{C}4'$), 85.90 ($\text{C}1'$), 111.12 ($\text{C}5$), 111.60 (Ph-o), 126.42 (Ph-m), 137.18 ($\text{C}6$), 138.29 (Ph-i), 150.22 ($\text{C}-2$), 153.06 (Ph-p), 163.58 ($\text{C}4$), 170.53 (CH_3COO), 170.85 (CH_3COO); UV(MeOH) $\lambda_{\text{max}} = 260$ nm ($\varepsilon = 8200$), $\lambda_{\text{max}} = 380$ nm ($\varepsilon = 16500$).

4h *Z* and *E* isomers; m/z (HRMS, FAB) 463.1447 ($[\text{M}+\text{H}]^+$ $\text{C}_{20}\text{H}_{23}\text{N}_4\text{O}_9$ requires 463.1465) ^1H NMR (250 MHz, CDCl_3) δ 2.12 (s, 3H, CH_3COO of *Z*), 2.13 (s, 3H, CH_3COO of *Z*), 2.09–2.23 (m, 10H, $2\times\text{CH}_3\text{COO}$ of *E*, $\text{H}2'$, $\text{H}2''$ of *Z* and *E*), 3.86 (dd, $^4J_{\text{H}6,\text{H}7} = 1.9$ Hz, $J_{\text{gem}} = 14.6$ Hz, 1H, one of CH_2 –6 of *E*), 3.98 (dd, $^4J_{\text{H}6,\text{H}7} = 0.9$ Hz, $J_{\text{gem}} = 13.5$ Hz, 1H, one of CH_2 –6 of *Z*), 4.12–4.46 (m, 7H, one of CH_2 –6, $\text{H}4'$ of *Z* and *E*, $\text{H}5'$, $\text{H}5''$ of *Z*, $\text{H}5''$ of *E*), 4.75 (dd, $J_{\text{H}5',\text{H}4'} = 9.9$ Hz, $J_{\text{gem}} = 12.1$ Hz, 1H, $\text{H}5'$ of *E*), 5.07–5.16 (m, 1H, $\text{H}3'$ of *Z* and *E*), 5.24 (m, 1H, PhNHCH of *E*), 6.35 (dd, $J_{\text{H}1',\text{H}2''} = 6.6$ Hz, $J_{\text{H}1',\text{H}2'} = 8.1$ Hz, 1H, $\text{H}1'$ of *Z*), 6.40 (m, 1H, $\text{H}1'$ of *E*), 7.05–7.16 (m, 2H, Ph-o of *Z*), 7.21–7.27 (m, 2H, Ph-o of *E*), 7.44 (d, $J = 12.1$ Hz, 1H, $\text{H}7$ of *Z*), 7.56 (s, 1H, $\text{NH}-3$ of *E*), 7.74 (s, 1H, $\text{NH}-3$ of *Z*), 8.18–8.29 (m, 5H, Ph-m of *Z* and *E*, $\text{H}7$ of *E*), 10.56 (d, $J_{\text{NH},\text{H}7} = 12.0$ Hz, 1H, PhNHCH of *Z*); ^{13}C NMR (63 MHz, CDCl_3) δ 20.99 (CH_3COO of *E* and *Z*), 21.10 (CH_3COO of *E* and *Z*), 33.04 ($\text{C}2'$ of *E*), 33.55 ($\text{C}2'$ of *Z*), 36.26 ($\text{C}6$ of *E*), 40.29 ($\text{C}6$ of *Z*), 64.03 ($\text{C}5'$ of *Z* and *E*), 74.26 ($\text{C}3'$ of *Z* and *E*), 80.96 ($\text{C}4'$ of *Z*), 81.96 ($\text{C}4'$ of *E*), 84.51 ($\text{C}1'$ of *Z*), 85.54 ($\text{C}1'$ of *E*), 95.06 ($\text{C}5$ of *Z*), 98.99 ($\text{C}5$ of *E*), 115.01 (Ph-o of *Z* and *E*), 126.25 (Ph-m of *Z* and *E*), 135.25 ($\text{C}7$ of *E*), 138.45 ($\text{C}7$ of *Z*), 142.75 (Ph-i of *E*), 142.85 (Ph-i of *E*), 145.58 (Ph-p of *E*), 145.71 (Ph-p of *Z*), 151.40 ($\text{C}2$ of *E*), 152.67 ($\text{C}2$ of *Z*), 164.55 ($\text{C}4$ of *E*), 166.94 ($\text{C}4$ of *Z*), 170.64 (CH_3COO of *Z* and *E*), 170.72, (CH_3COO of *Z* and *E*); UV(MeOH) $\lambda_{\text{max}} = 372.5$ nm ($\varepsilon = 21500$).

REFERENCES

1. Baxter, E.W.; Reitz, A.B. *Reductive Aminations of Carbonyl Compounds with Borohydride and Borane Reducing Agents*, Wiley, New York, 2002, vol. 59, pp. 1–759.
2. Brown, H.C.; Krishnamurthy, S. Forty years of hydride reductions. *Tetrahedron* **1979**, 35, 567–607.
3. Borch, R.F.; Bernstein, M.D.; Durst, H.D. Cyanohydridoborate anion as a selective reducing agent. *J. Am. Chem. Soc.* **1971**, 93, 2897–2904.
4. Abdel-Magid, A.F.; Carson, K.G.; Harris, B.D.; Maryanoff, C.A.; Shah, R.D. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. *J. Org. Chem.* **1996**, 61, 3849–3862.
5. Abdel-Magid, A.F.; Mehrman, S.J. A Review on the use of sodium triacetoxyborohydride in the reductive amination of ketones and aldehydes. *Org. Process Res. Dev.* **2006**, 10, 971–1031.
6. Gribble, G.W. The synthetic versatility of acyloxyborohydrides. *Org. Process Res. Dev.* **2006**, 10, 1062–1075.
7. Zatsepin, T.S.; Stetsenko, D.A.; Gait, M.J.; Oretskaya, T.S. Use of carbonyl group addition-elimination reactions for synthesis of nucleic acid conjugates. *Bioconjugate Chem.* **2005**, 16, 471–489.
8. Takeda, T.; Ikeda, K.; Mizuno, Y.; Ueda, T. Synthesis and properties of deoxyoligonucleotides containing putrescinylnthymine (nucleosides and nucleotides. LXXVI). *Chem. Pharm. Bull.* **1987**, 35, 3558–3567.
9. Godzina, P.; Markiewicz, W.T. Synthetic oligonucleotide combinatorial libraries. 4. Synthesis of 5-polyaminomethyl-2'-deoxyuridines. *Collect. Czech. Chem. Commun. Symp. Ser.* **1999**, 2, 79–82.
10. Kittaka, A.; Horii, C.; Kuze, T.; Asakura, T.; Ito, K.; Nakamura, K.T.; Miyasaka, T.; Inoue, J.I. Introduction of 5-formyl-2'-deoxyuridine into a kB site: Critical discrimination of a base structure in the major groove by NFkB p50 homodimer. *Synlett* **1999**, 869–872.
11. Catalanotti, B.; Galeone, A.; Mayol, L.; Oliviero, G.; Rigano, D.; Varra, N. Synthesis of 5-methylamino-2'-deoxyuridine derivatives. *Nucleosides Nucleotides Nucleic Acids* **2001**, 20, 1831–1841.
12. Verma, S.; Jager, S.; Thum, O.; Famulok, M. Functional tuning of nucleic acids by chemical modifications: Tailored oligonucleotides as drugs, devices, and diagnostics. *Chemical Record* **2003**, 3, 51–60.
13. Bittker, J.A.; Phillips, K.J.; Liu, D.R. Recent advances in the in vitro evolution of nucleic acids. *Curr. Opin. Chem. Biol.* **2002**, 6, 367–374.
14. Sochacka, E.; Smuga, D. Uracil ring opening in the reaction of 5-formyl-2'-deoxyuridine with primary alkyl amines. *Tetrahedron Lett.* **2007**, 48, 1363–1367.
15. Ono, A.; Okamoto, T.; Inada, M.; Nara, H.; Matsuda, A. Synthesis and properties of oligonucleotides containing 5-formyl-2'-deoxyuridine. *Chem. Pharm. Bull.* **1994**, 42, 2231–2237.
16. Stankovicova, H.; Lacova, M.; Gaplovsky, A.; Chovancova, J.; Pronayova, N.A. Reaction of 3-formylchromones with aromatic amino carboxylic acids. *Tetrahedron* **2001**, 57, 3455–3464.
17. Tonkikh, N.N.; Strakovs, A.; Petrova, M. N-monosubstituted 6-aminomethylene-5-oxo-2-phenyl-5,6,7,8-tetrahydroquinazolines. *Chem. Heterocycl. Comp.* **2005**, 41, 1053–1058.
18. Verbeure, B.; Lacey, C.J.; Froeyen, M.; Rozenski, J.; Herdewijn, P. Synthesis and cleavage experiments of oligonucleotide conjugates with a diimidazole-derived catalytic center. *Bioconjugate Chem.* **2002**, 13, 333–350.